Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PF 04457845

Known as: PF-04457845, PF04457845 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a…
BACKGROUND Cannabis is one of the most widely used drugs worldwide. Cannabis use disorder is characterised by recurrent use of… Expand
Is this relevant?
2017
2017
Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474
A recent phase 1 trial of the fatty acid amide hydrolase (FAAH) inhibitor BIA 10-2474 led to the death of one volunteer and… Expand
Is this relevant?
2015
2015
Blocking of Fatty Acid Amide Hydrolase Activity with PF-04457845 in Human Brain: A Positron Emission Tomography Study with the Novel Radioligand [11C]CURB
Positron emission tomography with [11C]CURB was recently developed to quantify fatty acid amide hydrolase (FAAH), the enzyme… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2013
2013
Synthesis and preclinical evaluation of [11C-carbonyl]PF-04457845 for neuroimaging of fatty acid amide hydrolase.
INTRODUCTION Fatty acid amide hydrolase (FAAH) has a significant role in regulating endocannabinoid signaling in the central… Expand
Is this relevant?
Highly Cited
2012
Highly Cited
2012
An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective…
The effect of PF-04457845, a potent and selective fatty acid amide hydrolase-1 (FAAH1) inhibitor, on pain due to osteoarthritis… Expand
Is this relevant?
2012
2012
Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects.
UNLABELLED AIMS To evaluate the pharmacology and tolerability of PF-04457845, an orally available fatty acid amide hydrolase-1… Expand
Is this relevant?
2012
2012
Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions.
Fatty-acid amide hydrolase (FAAH) catalyzes the intracellular hydrolysis of the endocannabinoid anandamide and other bioactive… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain.
The endogenous cannabinoid (endocannabinoid) anandamide is principally degraded by the integral membrane enzyme fatty acid amide… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
2011
2011
Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.
Fatty acid amide hydrolase (FAAH) is an integral membrane serine hydrolase that degrades the fatty acid amide family of signaling… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2011
2011
Mechanistic and pharmacological characterization of PF-04457845 : a highly potent and selective FAAH inhibitor that reduces inflammatory and noninflammatory pain
Pfizer Worldwide Research and Development, Groton, CT 06340, USA (K.A., Y.Z., C.S., D.S.J.); Ann Arbor, MI 48105, USA (K.A., S.E… Expand
  • table 1
  • table 2
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE